In a study of patients undergoing transperineal prostate biopsy, the detection rate of clinically significant prostate cancer did not differ significantly between targeted biopsy (TB) with fewer systematic biopsy (SB) cores and TB with SB of the whole prostate.
Increased age was significantly associated with increased odds of a decline in Sexual Health Inventory for Men category, a study found.
Although infection rates following prostate biopsy have stabilized, the rates of emergency department visits and hospitalizations for post-biopsy infections are increasing, a study found.
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
In a single center study, asymptomatic bacteriuria resolved before prostate biopsy, without additional treatment.
